In September 2016 we told you about the withdrawal of retigabine (Trobalt) from the market.
In April 2017,
was sent reminding relevant healthcare professionals that all patients must be withdrawn from Trobalt by the end of June 2017.
Withdrawal of a patient should be gradual and take place over at least 3 weeks, in accordance with the prescribing information.
Letters were also sent about the following medicines in April 2017:
- Orgalutran (ganirelix) 0.25 mg/0.5 mL:
- Cotellic▼ (cobimetinib):
, including dose modification recommendations
- Floran (epoprostenol):
- ERWINASE 181G:
—vials of ERWINASE from batch 181G should be used with a 5-micron filter needle
- Levetiracetam-containing products 100 mg/mL oral solution presentations:
- Amoxil (amoxicillin trihydrate):
Article citation: Drug Safety Update volume 10 issue 10, May 2017: 3.